Matthew T E McLaughlin is Chief Financial Officer of the Company since April 30, 2019. Before joining Oxford Immunotec, Mr. McLaughlin served as chief financial officer, US and Canada, at GE Healthcare from December 2016 through March 2019. Prior to that, Mr. McLaughlin worked at GE Aviation, serving as chief financial officer global supply chain from May 2014 to December 2016, chief financial officer GE avionics from March 2012 to April 2014 and executive, financial planning and analysis from 2009 to February 2012. Before that Mr. McLaughlin worked for General Electric as a member of the corporate audit staff, holding various positions and ultimately leading global audit coverage of three GE businesses, including GE Aviation.
As the Chief Financial Officer of Oxford Immunotec Global PLC, the total compensation of Matthew McLaughlin at Oxford Immunotec Global PLC is $1,288,150. There are 1 executives at Oxford Immunotec Global PLC getting paid more, with Peter Wrighton-Smith having the highest compensation of $2,151,490.
Matthew McLaughlin is 43, he's been the Chief Financial Officer of Oxford Immunotec Global PLC since 2019. There are 10 older and no younger executives at Oxford Immunotec Global PLC. The oldest executive at Oxford Immunotec Global PLC is Richard Sandberg, 77, who is the Independent Director.
Matthew's mailing address filed with the SEC is C/O OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, ABINGDON, OXFORDSHIRE, X0, OX14 4RZ.
Over the last 11 years, insiders at Oxford Immunotec Global PLC have traded over $13,598,906 worth of Oxford Immunotec Global PLC stock and bought 47,600 units worth $549,576 . The most active insiders traders include James R Tobin, Peter Wrighton Smith, and Ronald Asbury Andrews. On average, Oxford Immunotec Global PLC executives and independent directors trade stock every 36 days with the average trade being worth of $536,006. The most recent stock trade was executed by Patrick J Balthrop on 20 May 2020, trading 4,000 units of OXFD stock currently worth $49,920.
Oxford Immunotec Global PLC executives and other stock owners filed with the SEC include: